|
The latest from FDA
Public health emergency response and other updates from FDA since our last MCMi email include:
- August 16, 2022: FDA Roundup including a new web page to highlight Operation Lascar, which, with the United Kingdom, is the FDA’s first bilateral initiative focused on the movement of illicit FDA-regulated products
- August 16, 2022: Monkeypox response: The Jynneos vaccine EUA fact sheet for recipients and caregivers is now available in additional languages
- August 12, 2022: FDA Roundup including a safety communication advising people to perform repeat, or serial, testing following a negative result on any at-home COVID-19 antigen test
- August 12, 2022: Monkeypox response: Information for Blood Establishments Regarding the Monkeypox Virus and Blood Donation
- August 11, 2022: FDA Safety Communication: At-Home COVID-19 Antigen Tests-Take Steps to Reduce Your Risk of False Negative
- August 10, 2022: Monkeypox response: Dear Healthcare Provider letter (PDF), accompanying the EUA for Jynneos
Quick links: COVID-19 updates from FDA, FDA Monkeypox Response
|
|
|
Monkeypox response updates
Information for blood establishments regarding the monkeypox virus and blood donation
FDA posted a safety communication to provide information to blood establishments regarding monkeypox virus and blood donations. Worldwide, there have been no reports of transmission of monkeypox virus through blood transfusion and the risk of transfusion-transmission remains theoretical. The communication explains that existing safeguards for blood safety are likely to identify individuals who present to donate who are diagnosed with monkeypox virus or who are currently at the greatest risk for infection with monkeypox virus. Further, the FDA will continue to monitor cases of monkeypox in the U.S. and worldwide and the available information about potential risk of transfusion-transmitted monkeypox virus. The FDA will provide additional information as it becomes available. (August 12, 2022)
Jynneos vaccine EUA fact sheet translations
On August 9, 2022, FDA issued an EUA for the Jynneos vaccine to allow healthcare providers to use the vaccine by intradermal injection for individuals 18 years of age and older who are determined to be at high risk for monkeypox infection. The EUA fact sheet for recipients and caregivers is now available in additional languages. (August 16, 2022)
EUA fact sheet: Fact Sheet for Recipients and Caregivers about Jynneos (Smallpox and Monkeypox Vaccine, Live, Non-Replicating) (English)
|
COVID-19 testing: Safety communication
At-home COVID-19 antigen tests: Take steps to reduce your risk of false negative
FDA is advising people to perform repeat, or serial, testing following a negative result on any at-home COVID-19 antigen test, to reduce the risk an infection may be missed (false negative result) and to help prevent people from unknowingly spreading the SARS-CoV-2 virus to others. The FDA recommends repeat testing following a negative result whether or not you have COVID-19 symptoms. (August 11, 2022)
|
|
|
Emergency Use Authorization (EUA) updates
In vitro diagnostic (test) EUAs
As of August 16, 2022, 439 tests and sample collection devices are authorized by FDA under EUAs. These include 302 molecular tests and sample collection devices, 85 antibody and other immune response tests, 51 antigen tests, and 1 diagnostic breath test. There are 78 molecular authorizations and 1 antibody authorization that can be used with home-collected samples. There is 1 EUA for a molecular prescription at-home test, 2 EUAs for antigen prescription at-home tests, 19 EUAs for antigen over-the-counter (OTC) at-home tests, and 3 EUAs for molecular OTC at-home tests. FDA has authorized 31 antigen tests and 8 molecular tests for serial screening programs. The FDA has also authorized 1,084 revisions to test EUAs. Also see: COVID-19 Test Basics
|
|
|
Events
-
August 24, 2022: Virtual Town Hall Series - Coronavirus (COVID-19) Test Development and Validation, 12:05 - 1:00 p.m. ET, hosted by FDA's Center for Devices and Radiological Health (CDRH).
-
August 30, 2022: Virtual public workshop - Drug Development Considerations for the Prevention of Healthcare-Associated Infections - FDA and the Centers for Disease Control and Prevention (CDC) are co-sponsoring this workshop to discuss topics including the current state of development of pathogen-directed products used to prevent healthcare-associated infections, and antimicrobial resistance threats as potential targets for decolonization and pathogen reduction. To attend, register by 12:00 p.m. EDT August 29, 2022.
-
New! September 12-13, 2022: DIA-USFDA-PMDA-TGA-CDSCO Advanced Manufacturing Workshop (virtual, 5:30 - 9:30 a.m. EDT) - Embracing The Future: Regulatory Considerations And Industry Perspectives On Advanced Manufacturing - FDA's India Office and the Drug Information Association (DIA) India Office will host a two-day workshop on regulatory policies, guidance and support for the adoption of advanced manufacturing technologies.
-
September 19, 2022: FDA Workshop: Increasing the Efficiency of Biosimilar Development Programs (virtual) - The workshop will focus on comparative clinical studies associated with biosimilar development programs and will discuss possible innovative ideas that have the potential to streamline and improve the efficiency of biosimilar development. Advance registration required.
-
September 21-22, 2022: 2022 Public Meeting of the National Antimicrobial Resistance Monitoring System (NARMS) (virtual) - FDA, in cooperation with the U.S. Centers for Disease Control and Prevention and the U.S. Department of Agriculture’s Food Safety and Inspection Service, its partners in the National Antimicrobial Resistance Monitoring System (NARMS), opened registration for the 2022 Public Meeting of NARMS. The meeting is open to all stakeholders at no cost.
|
|
Information for industry and health care providers
COVID-19 therapeutics
Check out the FDA COVID-19 Drugs page for information including:
- The difference between FDA-approved drugs and drugs authorized under an EUA,
- Approved drugs for the treatment of COVID-19, and
- Types of EUA-authorized products including SARS-CoV-2-targeting monoclonal antibodies, antiviral drugs, immune modulators, sedatives, and renal replacement therapies.
FDA is committed to providing timely recommendations, regulatory information, guidance, and technical assistance necessary to support rapid COVID-19 response efforts. FDA has issued more than 75 COVID-19-related guidances to date.
|
|
In case you missed it
Resources to keep yourself and others safe from COVID-19 Find out where to get a COVID-19 vaccine, test, or treatment in your community at COVID.gov. Call 1-800-232-0233 (TTY 1-888-720-7489) with questions. (Also available in Spanish and Simplified Chinese.)
|
List of hand sanitizers consumers should not use Some hand sanitizers have been recalled and there are more than 350 hand sanitizers the FDA recommends you stop using right away. Bookmark www.fda.gov/handsanitizerlist for the latest, and use our step-by-step search guide to find out if your product is on the list.
|
Did someone forward you this email? Subscribe. (Select Emergency Preparedness and Response, FDA Medical Countermeasures Initiative (MCMi) News)
|
|
|
|
|